Emtricitabine/Tenofovir-DF (FTC/TDF, PrEP)
Quality of Evidence:
Coadministration has not been studied. Cisplatin is eliminated renally via OCT2 and MATE1: cisplatin and emtricitabine could potentially compete for MATE1, slowing their elimination. Based on metabolism and clearance a pharmacokinetic interaction is unlikely with tenofovir as it is eliminated by other renal transporters, however, coadministration may increase the risk of nephrotoxicity. If coadministration of emtricitabine/tenofovir-DF and cisplatin is necessary, close monitoring of renal function is recommended.
View all available interactions with
Emtricitabine/Tenofovir-DF (FTC/TDF, PrEP) by clicking